Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Deep Vein Thrombosis Data Bolster Xarelto's Overall Profile

This article was originally published in The Pink Sheet Daily

Executive Summary

A successful test as a single drug against two-step standard of care with Lovenox could help the Bayer/J&J anticoagulant stand out against its rivals.

You may also be interested in...



Apixaban Impresses At ESC, Leading To Speculation About An Early Filing

Bristol and Pfizer put an early end to the Phase III study successfully comparing their anticoagulant to aspirin, and the preliminary data bode well for further results due out mid-2011, but will they wait?

Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting

Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half Along With New Application For Chronic Use

Chronic use application may help ease FDA's reluctance to make available a much anticipated and broadly applicable anticoagulant for the acute application in the original NDA.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel